This project has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No 258868.

Welcome to the website of the LCAOS research project

The LCAOS project will develop and test a new diagnostic tool, able to detect:

  • the presence of lung cancer, and
  • an increased risk of a patient developing lung cancer in the future.

Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications. LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of lung cancer, and the presence of lung cancer. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath.

LCAOS will:

  1. develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs);
  2. test the ability of these devices to sense volatile lung cancer biomarkers from in-vitro tissue, and exhaled human breath;
  3. study the signal transduction mechanism of the volatile biomarkers, using pattern recognition;
  4. improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and
  5. perform clinical-related studies to assess lung cancer conditions in actual patients & tissues, and in the presence of real-world confounding signals.

Second Workshop on Lung Cancer Detection with Sensor Arrays

September, 18-19, 2014 – Majorca, Palma, Spain

Current lung cancer (LC) detection is far from being ideal. LC is the most lethal type of cancer, accounting for around 28% of cancer-related deaths globally. Its detection is usually accompanied by a late developmental stage and, therefore, a terrible prognosis. The tests that are being used nowadays are basically based on bronchoscope biopsies, pulmonary punctures, and computer tomography (CT), which often identify tumors at an intolerably late stage of the disease, occasionally miss tumors, and sometimes provide high rates of false positives, a fact that leads to over-utilization of the medical systems and to unnecessary medical procedures. Based on the results, it is obvious that there is, to say the least, room for improvement. There is no doubt that these methods are not suited for extensive screening as they are not efficient in terms of time and costs and, more importantly, are unpleasant for the patient and not free of complications. Detecting LC in its early stages, while still localized, may just be the way to lower the unbearably large mortality/incidence ratio LC originates, as it can be expected to increase the 5-year-survival rate by 3-4 times.

LCaos Newsletter - Issue no.4


Dear Readers,
You are welcome to our new issue of the LCaos Newsletter.  As you know, the purpose of this newsletter is to bring you the latest news coming from our FP7 LCaos consortium activities and achievements.